Agonistic behavior of PACAP6-38 on sensory nerve terminals and cytotrophoblast cells

D. Reglodi, R. Borzsei, T. Bagoly, A. Boronkai, B. Rácz, A. Tamás, P. Kiss, G. Horvath, R. Brubel, J. Németh, G. Tóth, Z. Helyes

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The effects of pituitary adenylate cyclase activating polypeptide (PACAP) are mediated through G-protein-coupled receptors, the specific PAC1 receptor and VPAC1 and VPAC2 receptors which bind vasoactive intestinal peptide with similar affinity. Based on binding affinity studies, PACAP6-38 was discovered as a potent antagonist of PAC1 and it has been used by hundreds of studies as a PACAP antagonist. Recently, we have found that in certain cells/tissues, PACAP6-38 does not antagonize PACAP-induced effects, but surprisingly, it exerts similar actions to PACAP1-38, behaving as an agonist. In the present study, we report on the agonistic behavior of PACAP6-38 on neuropeptide release from sensory nerves of the isolated rat trachea and on the MAPK signaling pathways in cytotrophoblast cells. In isolated rat tracheae, PACAP6-38, similarly to PACAP1-38, induced significant inhibitory effects on the release of three simultaneously measured sensory neuropeptides, substance P, calcitonin gene-related peptide, and somatostatin evoked by both chemical excitation and electrical field stimulation of capsaicin-sensitive afferents. Effects of PACAP6-38 were the same as those of PACAP1-38 on MAPK signaling in human cytotrophoblast cells. Western blot analysis showed that both peptide forms stimulated ERK1/2 and JNK phosphorylation, while they both inhibited p38 MAPK phosphorylation. The most pronounced effects were observed when both peptides were present. In summary, our results show that PACAP6-38, which is a PACAP receptor antagonist in most cells/tissues, can behave as an agonist in other systems. The increasing interest in the effects of PACAP requires further studies on the pharmacological properties of the peptide and its analogues.

Original languageEnglish
Pages (from-to)270-278
Number of pages9
JournalJournal of Molecular Neuroscience
Volume36
Issue number1-3
DOIs
Publication statusPublished - Nov 2008

Fingerprint

Agonistic Behavior
Pituitary Adenylate Cyclase-Activating Polypeptide
Trophoblasts
Trachea
Neuropeptides
Peptides
Receptors, Vasoactive Intestinal Peptide, Type II
Receptors, Vasoactive Intestinal Polypeptide, Type I
Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I
Pituitary Adenylate Cyclase-Activating Polypeptide Receptors
Phosphorylation
Calcitonin Gene-Related Peptide
Capsaicin
Vasoactive Intestinal Peptide
p38 Mitogen-Activated Protein Kinases
Substance P
G-Protein-Coupled Receptors
Somatostatin
Electric Stimulation
Western Blotting

Keywords

  • Analogue
  • CGRP
  • JAR cytotrophoblast
  • PACAP fragment
  • Somatostatin
  • Substance P

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

Agonistic behavior of PACAP6-38 on sensory nerve terminals and cytotrophoblast cells. / Reglodi, D.; Borzsei, R.; Bagoly, T.; Boronkai, A.; Rácz, B.; Tamás, A.; Kiss, P.; Horvath, G.; Brubel, R.; Németh, J.; Tóth, G.; Helyes, Z.

In: Journal of Molecular Neuroscience, Vol. 36, No. 1-3, 11.2008, p. 270-278.

Research output: Contribution to journalArticle

@article{72db5befb83f4659b3d93df23c8b83a2,
title = "Agonistic behavior of PACAP6-38 on sensory nerve terminals and cytotrophoblast cells",
abstract = "The effects of pituitary adenylate cyclase activating polypeptide (PACAP) are mediated through G-protein-coupled receptors, the specific PAC1 receptor and VPAC1 and VPAC2 receptors which bind vasoactive intestinal peptide with similar affinity. Based on binding affinity studies, PACAP6-38 was discovered as a potent antagonist of PAC1 and it has been used by hundreds of studies as a PACAP antagonist. Recently, we have found that in certain cells/tissues, PACAP6-38 does not antagonize PACAP-induced effects, but surprisingly, it exerts similar actions to PACAP1-38, behaving as an agonist. In the present study, we report on the agonistic behavior of PACAP6-38 on neuropeptide release from sensory nerves of the isolated rat trachea and on the MAPK signaling pathways in cytotrophoblast cells. In isolated rat tracheae, PACAP6-38, similarly to PACAP1-38, induced significant inhibitory effects on the release of three simultaneously measured sensory neuropeptides, substance P, calcitonin gene-related peptide, and somatostatin evoked by both chemical excitation and electrical field stimulation of capsaicin-sensitive afferents. Effects of PACAP6-38 were the same as those of PACAP1-38 on MAPK signaling in human cytotrophoblast cells. Western blot analysis showed that both peptide forms stimulated ERK1/2 and JNK phosphorylation, while they both inhibited p38 MAPK phosphorylation. The most pronounced effects were observed when both peptides were present. In summary, our results show that PACAP6-38, which is a PACAP receptor antagonist in most cells/tissues, can behave as an agonist in other systems. The increasing interest in the effects of PACAP requires further studies on the pharmacological properties of the peptide and its analogues.",
keywords = "Analogue, CGRP, JAR cytotrophoblast, PACAP fragment, Somatostatin, Substance P",
author = "D. Reglodi and R. Borzsei and T. Bagoly and A. Boronkai and B. R{\'a}cz and A. Tam{\'a}s and P. Kiss and G. Horvath and R. Brubel and J. N{\'e}meth and G. T{\'o}th and Z. Helyes",
year = "2008",
month = "11",
doi = "10.1007/s12031-008-9089-z",
language = "English",
volume = "36",
pages = "270--278",
journal = "Journal of Molecular Neuroscience",
issn = "0895-8696",
publisher = "Humana Press",
number = "1-3",

}

TY - JOUR

T1 - Agonistic behavior of PACAP6-38 on sensory nerve terminals and cytotrophoblast cells

AU - Reglodi, D.

AU - Borzsei, R.

AU - Bagoly, T.

AU - Boronkai, A.

AU - Rácz, B.

AU - Tamás, A.

AU - Kiss, P.

AU - Horvath, G.

AU - Brubel, R.

AU - Németh, J.

AU - Tóth, G.

AU - Helyes, Z.

PY - 2008/11

Y1 - 2008/11

N2 - The effects of pituitary adenylate cyclase activating polypeptide (PACAP) are mediated through G-protein-coupled receptors, the specific PAC1 receptor and VPAC1 and VPAC2 receptors which bind vasoactive intestinal peptide with similar affinity. Based on binding affinity studies, PACAP6-38 was discovered as a potent antagonist of PAC1 and it has been used by hundreds of studies as a PACAP antagonist. Recently, we have found that in certain cells/tissues, PACAP6-38 does not antagonize PACAP-induced effects, but surprisingly, it exerts similar actions to PACAP1-38, behaving as an agonist. In the present study, we report on the agonistic behavior of PACAP6-38 on neuropeptide release from sensory nerves of the isolated rat trachea and on the MAPK signaling pathways in cytotrophoblast cells. In isolated rat tracheae, PACAP6-38, similarly to PACAP1-38, induced significant inhibitory effects on the release of three simultaneously measured sensory neuropeptides, substance P, calcitonin gene-related peptide, and somatostatin evoked by both chemical excitation and electrical field stimulation of capsaicin-sensitive afferents. Effects of PACAP6-38 were the same as those of PACAP1-38 on MAPK signaling in human cytotrophoblast cells. Western blot analysis showed that both peptide forms stimulated ERK1/2 and JNK phosphorylation, while they both inhibited p38 MAPK phosphorylation. The most pronounced effects were observed when both peptides were present. In summary, our results show that PACAP6-38, which is a PACAP receptor antagonist in most cells/tissues, can behave as an agonist in other systems. The increasing interest in the effects of PACAP requires further studies on the pharmacological properties of the peptide and its analogues.

AB - The effects of pituitary adenylate cyclase activating polypeptide (PACAP) are mediated through G-protein-coupled receptors, the specific PAC1 receptor and VPAC1 and VPAC2 receptors which bind vasoactive intestinal peptide with similar affinity. Based on binding affinity studies, PACAP6-38 was discovered as a potent antagonist of PAC1 and it has been used by hundreds of studies as a PACAP antagonist. Recently, we have found that in certain cells/tissues, PACAP6-38 does not antagonize PACAP-induced effects, but surprisingly, it exerts similar actions to PACAP1-38, behaving as an agonist. In the present study, we report on the agonistic behavior of PACAP6-38 on neuropeptide release from sensory nerves of the isolated rat trachea and on the MAPK signaling pathways in cytotrophoblast cells. In isolated rat tracheae, PACAP6-38, similarly to PACAP1-38, induced significant inhibitory effects on the release of three simultaneously measured sensory neuropeptides, substance P, calcitonin gene-related peptide, and somatostatin evoked by both chemical excitation and electrical field stimulation of capsaicin-sensitive afferents. Effects of PACAP6-38 were the same as those of PACAP1-38 on MAPK signaling in human cytotrophoblast cells. Western blot analysis showed that both peptide forms stimulated ERK1/2 and JNK phosphorylation, while they both inhibited p38 MAPK phosphorylation. The most pronounced effects were observed when both peptides were present. In summary, our results show that PACAP6-38, which is a PACAP receptor antagonist in most cells/tissues, can behave as an agonist in other systems. The increasing interest in the effects of PACAP requires further studies on the pharmacological properties of the peptide and its analogues.

KW - Analogue

KW - CGRP

KW - JAR cytotrophoblast

KW - PACAP fragment

KW - Somatostatin

KW - Substance P

UR - http://www.scopus.com/inward/record.url?scp=58149103069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149103069&partnerID=8YFLogxK

U2 - 10.1007/s12031-008-9089-z

DO - 10.1007/s12031-008-9089-z

M3 - Article

C2 - 18607779

AN - SCOPUS:58149103069

VL - 36

SP - 270

EP - 278

JO - Journal of Molecular Neuroscience

JF - Journal of Molecular Neuroscience

SN - 0895-8696

IS - 1-3

ER -